Considering the difficulties of drug development for transcription factor due to its structural disorder and involvement in various pathways, we have taken a different approach to identify a candidate therapeutic target for FOXA1 mutant prostate cancer using its own molecular characteristics [40]. The gene discussed is FOXA1; the disease is prostate carcinoma.